ACT Signature Webinars

Preclinical Considerations for Cell-Based Immunotherapies 

06-01-2018 09:30 AM

Hosted by the American College of Toxicology in Collaboration with the British Toxicology Society, the Society of Toxicologic Pathology, and the Teratology Society

Speaker: Allen K. Wensky, PhD, Biologist, Master Pharmacology/Toxicology Reviewer, US FDA

Abstract for Preclinical Considerations for Cell-Based Immunotherapies:

The general content and format of pharmacology/toxicology information to be included in the submission of an IND can be found in 21 CFR 312.23 (a)(8). The regulation states that “The kind duration, and scope of animal and other tests required vary with the duration and nature of the proposed clinical investigations.” The design and conduct of preclinical pharmacological and toxicological studies are thus important to inform regulatory decisions regarding the administration of an investigational cellular immunotherapy product in humans. These considerations will be discussed in addition to available FDA guidances, including FDA “Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products”. Lastly, the presentation will highlight the mechanisms for early communication with pharmacology/toxicology staff in CBER’s Office of Tissues and Advanced Therapies (OTAT) to obtain feedback on the preclinical development program.

View Webinar Recording

Webinar materials are property of the speaker and the American College of Toxicology and are intended for use by the host society and co-host societies' members for educational purposes only. Any distribution or copy of the materials is prohibited. By downloading from the link provided you agree to the terms expressed above.

Statistics
0 Favorited
15 Views
1 Files
0 Shares
3 Downloads
Attachment(s)
pdf file
Cellular Therapies Webinar Final.pdf   576 KB   1 version
Uploaded - 08-27-2020

Related Entries and Links

No Related Resource entered.